Novel combinations with oxaliplatin

Sridhar Mani, Jane Manalo, David Bregman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Oxaliplatin (Eloxatin) is a novel antineoplastic platinum derivative that may exert its cytotoxic effects by blocking DNA replication/transcription, thus resulting in cell death in proliferating cells, as well as apoptosis. Oxaliplatin is often more potent than other platinums such as cisplatin (Platinol) in vitro, and shows greater efficacy in preclinical studies against many tumor cell lines, including some that are resistant to cisplatin and carboplatin (Paraplatin). Oxaliplatin is approved for use with the fluoropyrimidines in the treatment of metastatic colorectal cancer in Asia, Latin America, and Europe. In light of the broad efficacy of oxaliplatin in several solid tumors and the encouraging preclinical data on combination therapy with novel agents (eg, thymidylate synthase inhibitors, epidermal growth factor-receptor antagonists, microtubule interactive agents), this article will review the published literature on novel combinations that have been tested in the laboratory and/or the clinic.

Original languageEnglish (US)
Pages (from-to)52-58
Number of pages7
JournalOncology
Volume14
Issue number12 SUPPL. 11
StatePublished - 2000

Fingerprint

oxaliplatin
Cisplatin
Carboplatin
Thymidylate Synthase
Latin America
Platinum
Tumor Cell Line
DNA Replication
Epidermal Growth Factor Receptor
Microtubules
Antineoplastic Agents
Colorectal Neoplasms
Cell Death
Apoptosis

ASJC Scopus subject areas

  • Oncology

Cite this

Mani, S., Manalo, J., & Bregman, D. (2000). Novel combinations with oxaliplatin. Oncology, 14(12 SUPPL. 11), 52-58.

Novel combinations with oxaliplatin. / Mani, Sridhar; Manalo, Jane; Bregman, David.

In: Oncology, Vol. 14, No. 12 SUPPL. 11, 2000, p. 52-58.

Research output: Contribution to journalArticle

Mani, S, Manalo, J & Bregman, D 2000, 'Novel combinations with oxaliplatin', Oncology, vol. 14, no. 12 SUPPL. 11, pp. 52-58.
Mani S, Manalo J, Bregman D. Novel combinations with oxaliplatin. Oncology. 2000;14(12 SUPPL. 11):52-58.
Mani, Sridhar ; Manalo, Jane ; Bregman, David. / Novel combinations with oxaliplatin. In: Oncology. 2000 ; Vol. 14, No. 12 SUPPL. 11. pp. 52-58.
@article{1f86beab05db4343a3dcc4b0f65b8f79,
title = "Novel combinations with oxaliplatin",
abstract = "Oxaliplatin (Eloxatin) is a novel antineoplastic platinum derivative that may exert its cytotoxic effects by blocking DNA replication/transcription, thus resulting in cell death in proliferating cells, as well as apoptosis. Oxaliplatin is often more potent than other platinums such as cisplatin (Platinol) in vitro, and shows greater efficacy in preclinical studies against many tumor cell lines, including some that are resistant to cisplatin and carboplatin (Paraplatin). Oxaliplatin is approved for use with the fluoropyrimidines in the treatment of metastatic colorectal cancer in Asia, Latin America, and Europe. In light of the broad efficacy of oxaliplatin in several solid tumors and the encouraging preclinical data on combination therapy with novel agents (eg, thymidylate synthase inhibitors, epidermal growth factor-receptor antagonists, microtubule interactive agents), this article will review the published literature on novel combinations that have been tested in the laboratory and/or the clinic.",
author = "Sridhar Mani and Jane Manalo and David Bregman",
year = "2000",
language = "English (US)",
volume = "14",
pages = "52--58",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "12 SUPPL. 11",

}

TY - JOUR

T1 - Novel combinations with oxaliplatin

AU - Mani, Sridhar

AU - Manalo, Jane

AU - Bregman, David

PY - 2000

Y1 - 2000

N2 - Oxaliplatin (Eloxatin) is a novel antineoplastic platinum derivative that may exert its cytotoxic effects by blocking DNA replication/transcription, thus resulting in cell death in proliferating cells, as well as apoptosis. Oxaliplatin is often more potent than other platinums such as cisplatin (Platinol) in vitro, and shows greater efficacy in preclinical studies against many tumor cell lines, including some that are resistant to cisplatin and carboplatin (Paraplatin). Oxaliplatin is approved for use with the fluoropyrimidines in the treatment of metastatic colorectal cancer in Asia, Latin America, and Europe. In light of the broad efficacy of oxaliplatin in several solid tumors and the encouraging preclinical data on combination therapy with novel agents (eg, thymidylate synthase inhibitors, epidermal growth factor-receptor antagonists, microtubule interactive agents), this article will review the published literature on novel combinations that have been tested in the laboratory and/or the clinic.

AB - Oxaliplatin (Eloxatin) is a novel antineoplastic platinum derivative that may exert its cytotoxic effects by blocking DNA replication/transcription, thus resulting in cell death in proliferating cells, as well as apoptosis. Oxaliplatin is often more potent than other platinums such as cisplatin (Platinol) in vitro, and shows greater efficacy in preclinical studies against many tumor cell lines, including some that are resistant to cisplatin and carboplatin (Paraplatin). Oxaliplatin is approved for use with the fluoropyrimidines in the treatment of metastatic colorectal cancer in Asia, Latin America, and Europe. In light of the broad efficacy of oxaliplatin in several solid tumors and the encouraging preclinical data on combination therapy with novel agents (eg, thymidylate synthase inhibitors, epidermal growth factor-receptor antagonists, microtubule interactive agents), this article will review the published literature on novel combinations that have been tested in the laboratory and/or the clinic.

UR - http://www.scopus.com/inward/record.url?scp=84866835053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866835053&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 52

EP - 58

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 12 SUPPL. 11

ER -